Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0
Outlook Therapeutics CEO Robert Jahr recently acquired 151,515 shares of common stock and an equal number of warrants. This transaction occurred at a combined public offering price of $0.99 per unit, amounting to $0, with each warrant allowing the purchase of one share at …